Lv31
222 积分 2023-12-04 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
1个月前
已完结
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
1个月前
已完结
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
1个月前
已完结
Nonhuman Primate Models in Biomedical Research
1个月前
已完结
Safety and tolerability of intrarectal perfluorodecalin for enteral ventilation in a first-in-human trial
3个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
4个月前
已完结
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
4个月前
已完结
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis
4个月前
已完结
皖公网安备34019202002308
